Including Sexually and Gender Diverse Populations in 3,4-Methylenedioxymethamphetamine-Assisted Psychotherapy Trial Research.
LGBT health – January 01, 2024
Source: PubMed
Summary
MDMA-assisted psychotherapy shows remarkable promise for treating PTSD, particularly among sexually and gender diverse individuals who face higher rates of trauma due to societal stigma and minority stress. Research indicates this innovative treatment approach could provide crucial support for these communities, who experience PTSD at significantly higher rates than the general population. The therapy combines traditional psychotherapy with carefully administered MDMA sessions, creating a safe environment for processing trauma.
Abstract
Sexually and gender diverse (SGD) populations experience an increased prevalence and severity of posttraumatic stress disorder (PTSD) compared with the general population. Minority stress theory contextualizes this increased disease burden by outlining how stigma and discrimination (e.g., homophobia and transphobia) contribute to worse mental health outcomes. The standard-of-care pharmacotherapy for PTSD is associated with significant treatment resistance. 3,4-Methylenedioxymethamphetamine (MDMA)-assisted psychotherapy (MDMA-AP) has emerged as an investigational treatment for PTSD but has lacked consideration for SGD populations. This article explores next steps in clinical trial design and implementation for the study of MDMA-AP with SGD populations who have PTSD.